TROMBOPOIETIN RECEPTOR AGONIST TREATMENT IN IDIOPATHIC THROMBOCYTOPENIC PURPURA

M.H. García Lagunar¹, I. Español Morales², M. Martínez Penella¹, I. Muñoz García¹, M.d.R. Gutiérrez Cívicos¹, E. Ferris Villanueva¹, R. Guerrero Bautista¹, A. García Márquez¹, D. Lacruz Guzmán¹, M.S. García Simón¹.

¹Hospital General Universitario Santa Lucía, Farmacia Hospitalaria, Cartagena, Spain.



BACKGROUND: Primary Immune Thrombocytopenia (ITP) is a disease characterized by decreased platelet count due to an accelerated platelet destruction and a reduced of platelet production. Romiplostim and eltrombopag are thrombopoietin receptor agonists (TRA) that stimulate platelet production and they constitute a new therapeutic group for this disease.

<u>PURPOSE</u>: To evaluate the effectiveness and safety of TRA in patients with ITP in an university general hospital.

MATERIALS AND METHODS: Retrospective observational study including patients with ITP who were treated with TRA.

☐ Age☐ Genre☐ Previo


00000

Previous treatments including splenectomy statusDuration and response to treatment


□ Side effects


Data collected:

RESULTS: From October 2009 to July 2014, fourteen patients with ITP were treated with TRA.



48.0±16.7 years old





Only one patient had been splenectomised before the treatment.

Average treatment duration:

6.6±5.3 months in the group of **romiplostim**

7.1±5.9 months in the group of **eltrombopag**

No side effects with the exception of one deep venous thrombosis (DVT) with eltrombopag

Response to treatment:

Eltrombopag:

4 complete responses (57.1%)

3 responses (42.9%)

Romiplostim:

1 complete response (50.0%)

1 response (50.0%)

Group with both drugs:

- 3 complete responses (60.0%)
- 1 no response (20.0%)
- 1 complete remission sustained after stop the treatment (20.0%)

CONCLUSIONS:

- •TRA present very high response rates including the possibility of complete remissions and sustained remissions after having stopped the treatment.
- ■Tolerance of TRA is good although it is important to keep an eye on the appearance of DVT.
- Patients with ITP, despite having received multiple lines of treatment, respond effectively to TRA.



²Hospital General Universitario Santa Lucía, Hematología, Cartagena, Spain.